相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2002
已完成
2
50.0%
招募中
1
25.0%
撤回
1
25.0%
暂无批准数据
- A new study published in Alzheimer's Research & Therapy demonstrates that SuperAgers cannot be distinguished from cognitively average peers based on APOE or Alzheimer's polygenic risk scores. - Researchers analyzed 142 SuperAgers and 89 cognitively average older adults across five U.S. and Canadian sites, finding no increased prevalence of rare protective genetic variants among SuperAgers. - The findings reinforce that preserving cognitive health involves more than reducing Alzheimer's disease risk alone, pointing toward protective biological, behavioral, and social pathways. - The study establishes that memory decline is not inevitable, with some individuals maintaining youthful memory into their 80s and beyond through mechanisms beyond genetics.
- The International Myeloma Foundation's M-Power initiative addresses stark health disparities where Black patients with multiple myeloma live half as long as White patients despite responding equally well to treatment. - The program operates through three pillars: community engagement, primary care education, and enhanced patient care, including a new diversity in clinical trials program featuring patient testimonials. - Despite representing 20% of new multiple myeloma cases (projected to reach 25% by 2034), Black patients comprise only 5-8% of clinical trial participants, highlighting the urgent need for improved representation.
- Researchers from TGen and Lundquist Institute have identified SARS-CoV-2 protein fragments in extracellular vesicles as a potential biomarker for long COVID, offering the first specific diagnostic indicator for the condition. - The study analyzed blood samples from 14 long COVID patients and found 65 distinct viral protein fragments from the virus's Pp1ab protein within extracellular vesicles, which were not detected in pre-pandemic control samples. - While promising, the biomarker showed subtle molecular signals that were not consistently detected at every blood collection time point, requiring further validation studies to determine clinical utility. - The findings add to evidence suggesting SARS-CoV-2 may persist in body tissues long after initial infection, though researchers remain uncertain whether the detected fragments represent ongoing viral replication or cellular debris.
- A systematic review of phase 3 trials reveals that all androgen receptor pathway inhibitors (ARPIs) demonstrate comparable efficacy outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients regardless of disease volume or metastasis timing. - Drug selection should prioritize patient-specific factors including comorbidities, toxicity profiles, and potential drug-drug interactions, with abiraterone and darolutamide showing fewer severe drug interactions compared to enzalutamide and apalutamide. - While enzalutamide may offer a slight benefit over abiraterone for patients with low-volume or de novo metastatic disease, experts emphasize that this difference is marginal and should not be the primary consideration for treatment selection.
